Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease

Rory Wolfe,James B Wetmore,Robyn L Woods,John J McNeil,Hugh Gallagher,Paul Roderick,Rowan Walker,Mark R Nelson,Christopher M Reid,Raj C Shah,Michael E Ernst,Jessica E Lockery,Andrew M Tonkin,Walter P Abhayaratna,Peter Gibbs,Erica M Wood,Suzanne E Mahady,Jeff D Williamson,Geoffrey A Donnan,Geoffrey C Cloud,Anne M Murray,Kevan R Polkinghorne

DOI: https://doi.org/10.1016/j.kint.2020.08.011

Abstract:The role of aspirin for primary prevention in older adults with chronic kidney disease (CKD) is unclear. Therefore, post hoc analysis of the randomized controlled trial ASPirin in Reducing Events in the Elderly (ASPREE) was undertaken comparing 100 mg of enteric-coated aspirin daily against matching placebo. Participants were community dwelling adults aged 70 years and older in Australia, 65 years and older in the United States, all free of a history of dementia or cardiovascular disease and of any disease expected to lead to death within five years. CKD was defined as present at baseline if either eGFR under 60mL/min/1.73m2 or urine albumin to creatinine ratio 3 mg/mmol or more. In 4758 participants with and 13004 without CKD, the rates of a composite endpoint (dementia, persistent physical disability or death), major adverse cardiovascular events and clinically significant bleeding in the CKD participants were almost double those without CKD. Aspirin's effects as estimated by hazard ratios were generally similar between CKD and non-CKD groups for dementia, persistent physical disability or death, major adverse cardiovascular events and clinically significant bleeding. Thus, in our analysis aspirin did not improve outcomes in older people while increasing the risk of bleeding, with mostly consistent effects in participants with and without CKD.